Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 178
Review of the Fialuridine (FIAU) Clinical Trials C Institute of Medicine Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials First Committee Meeting Monday and Tuesday, July 25-26, 1994 The Foundry Building (Room 2004) AGENDA MONDAY, July 25, 1994 8:30 a.m. EXECUTIVE SESSION Welcoming remarks, introductions and charge to committee Joseph S. Cassells, M.D. (IOM Interim Executive Officer) Morton Swartz, M.D. (Professor of Medicine, Harvard Medical School; Chief, James Jackson Firm; and Emeritus Chief, Infectious Disease Unit, Medical Services, Massachusetts General Hospital) Frederick J. Manning, Ph.D. (Study Director) Discussion of bias/conflict of interest issues Joseph Cassells 10:15 a.m. Break 10:30 a.m. Findings of the FDA Office of Compliance Mary L. Richardson (Acting Director, Division of Scientific Investigations, Office of Compliance, CDER, U.S. Food and Drug Administration)
OCR for page 179
Review of the Fialuridine (FIAU) Clinical Trials Ross Pierce, M.D. (Medical Officer, Clinical Investigations Branch, Division of Scientific Investigations, Office of Compliance, (CDER), U.S. Food and Drug Administration) 12:00 Noon Luncheon Buffet, Meeting Room 2004 1:00 p.m. Report of the FDA Task Force on Fialuridine: Hepatic and Pancreatic Toxicity Roger L. Williams, M.D. (Associate Director for Science and Medical Affairs, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration) 2:00 p.m. Role of the Division of Anti-Vital Drug Products David Feigal, M.D. (Director, Division of Anti-Viral Drug Products, Office of Drug Evaluation, CDER, U.S. Food and Drug Administration) 3:15 p.m. Break 3:30 p.m. Review of Studies R91-010 and PPPC Jay H. Hoofnagle, M.D. (Director, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health) 5:00 p.m. Meeting Adjourns for the Day TUESDAY, July 26, 1994 8:00 a.m. Review of Studies R89-001 and R90-001 Lawrence Corey, M.D. (Professor, Laboratory Medicine, Microbiology and Medicine, Virology Office, University of Washington, Seattle)
OCR for page 180
Review of the Fialuridine (FIAU) Clinical Trials Douglas D. Richman, M.D. (Professor of Pathology and Medicine, University of California, San Diego) Stephen E. Straus, M.D. (Chief Laboratory of Clinical Investigation, Medical Virology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health) 10:00 a.m. Review of Preclinical Studies John Emmerson, Ph.D. (Distinguished Lilly Research Scholar, Toxicology Division, Eli Lilly) 11:00 a.m. Eli Lilly Overview Donald G. Therasse, M.D. (Director, Anti-Infective Division, Eli Lilly Research Laboratories ) Allan J. Weinstein, M.D. (Vice President, Eli Lilly Research Laboratories) 12:15 p.m. Lunch, Meeting Room 2004 1:00 p.m. Report to the Director, NIH, of the Director's Advisory Committee's (DAC) Subcommittee to Review FIAU Studies David R. Challoner, M.D. (Vice-President for Health Affairs, University of Florida) David M. Kipnis, M.D. (Distinguished University Professor of Medicine, Washington University School of Medicine) 2:15 p.m. EXECUTIVE SESSION Barbara Rice, NAS Office of News and Public Information Discussion of Work Plan 3:00 p.m. Break 3:15 p.m. Continuation of Work Plan Discussion
OCR for page 181
Review of the Fialuridine (FIAU) Clinical Trials 5:00 p.m. Adjourn INSTITUTE OF MEDICINE COMMITTEE TO REVIEW THE FIALURIDINE (FIAU/FIAC) CLINICAL TRIALS Second Committee Meeting Thursday and Friday, September 8-9, 1994 Cecil and Ida Green Building Room 116 AGENDA THURSDAY, Sept. 8, 1994 8:00 a.m. EXECUTIVE SESSION (study outline; tape; report on patient interviews ) 9:30 a.m. Presentations to the Committee Judith Fallon, M.D. (Former Chair, Institutional Review Board NIAID) Howard Austin, M.D. (Chair, Institutional Review Board NIDDK) 10:30 a.m. David Feigel, M.D. (Director, Antiviral Drug Division CDER, FDA) 12:00 Noon Lunch 1:00 p.m. Continuation of presentations Barbara Savarese, R.N. (Study Coordinator R-90, R-91, 6-mo. trials) 2:00 p.m. Robin McKenzie, M.D. (Medical Officer, NIAID, Associate Investigator, 6 mos. trial)
OCR for page 182
Review of the Fialuridine (FIAU) Clinical Trials 3:00 p.m. Yoon Park, R.N. (Clinical Nurse, Warren Grant Magnuson Clinical Center, R-90, R-91, 6-mo. studies) 4:00 p.m. EXECUTIVE SESSION 5:00 p.m. Meeting Adjourns for the Day FRIDAY, Sept. 9, 1994 8:00 a.m. Presentations to the Committee Peter Barton Hutt, LL.D. (Former General Counsel FDA) 10:00 a.m. Mary Richardson (Deputy Director, Division of Scientific Investigations, Office of Compliance, CDER, FDA) Ross Pierce, M.D. (Division of Scientific Investigations, Office of Compliance CDER) 12:00 p.m. Lunch 1:00 p.m. EXECUTIVE SESSION (study plan, writing assignments, info needs) INSTITUTE OF MEDICINE COMMITTEE TO REVIEW THE FIALURIDINE (FIAU/FIAC) CLINICAL TRIALS Third Committee Meeting Wednesday and Thursday, November 16-17, 1994 The Foundry Building Room 2004 AGENDA WEDNESDAY, Nov. 16, 1994 8:30 a.m. Review of Draft Report Sections Each author in turn; see attached outline
OCR for page 183
Review of the Fialuridine (FIAU) Clinical Trials 10:15 a.m. Break 10:30 a.m. Resume Review of Draft Sections 12:00 Noon Luncheon Buffet, Meeting Room 2004 1:00 p.m. Assemble Recommendations and Conclusions 2:30 p.m. Break 3:00 p.m. Revision of Report Sections On laptops in 2004 or at HSPD Offices 5:00 p.m. Meeting Adjourns for the Day THURSDAY, Nov. 17, 1994 8:00 a.m. Review of Revised and New Sections 10:15 a.m. Break 10:30 a.m. Resume Review 12:00 p.m. Lunch, Meeting Room 2004 1:00 p.m. Resume Review 3:15 p.m. Rewrites as necessary 5:00 p.m. Adjourn
Representative terms from entire chapter: